Adaptive Biotechnologies Corp [ADPT] stock is trading at $8.38, up 9.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADPT shares have gain 5.54% over the last week, with a monthly amount glided 11.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on March 21, 2025, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $9 for it. On January 05, 2023, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $15 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $14 on December 21, 2022. Credit Suisse initiated its recommendation with a Underperform and recommended $8 as its price target on August 25, 2022. Piper Sandler started tracking with a Neutral rating for this stock on June 03, 2022, and assigned it a price target of $7.50. In a note dated February 16, 2022, JP Morgan reiterated an Overweight rating on this stock and revised its target price from $75 to $50.
Adaptive Biotechnologies Corp [ADPT] stock has fluctuated between $2.28 and $9.01 over the past year. Currently, Wall Street analysts expect the stock to reach $12.33 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $8.38 at the most recent close of the market. An investor can expect a potential return of 47.14% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Adaptive Biotechnologies Corp [NASDAQ:ADPT] reported sales of 178.96M for the trailing twelve months, which represents a growth of 3.66%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.89%, and Net Profit Margin reading is -0.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.68 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.58 points at the first support level, and at 6.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.89, and for the 2nd resistance point, it is at 9.41.
Ratios To Look Out For
For context, Adaptive Biotechnologies Corp’s Current Ratio is 2.89. On the other hand, the Quick Ratio is 2.81, and the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 6.96, the price to book ratio is 6.11.
Transactions by insiders
Recent insider trading involved ROBINS HARLAN S, Chief Scientific Officer, that happened on Mar 24 ’25 when 1698.0 shares were sold. Officer, Harlan Robins completed a deal on Mar 24 ’25 to buy 1698.0 shares. Meanwhile, Director GRIFFIN MICHELLE RENEE sold 36291.0 shares on Mar 13 ’25.
